Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company’s proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.
Navigation
Daily News
- GTCR invests in ATI Holdings
- Regado Biosciences announces first successful subcutaneous application of an aptamer
- Kevin P. Black, MD, Elected To American Academy Of Orthopaedic Surgeons Board Of Directors
- AngioScore Announces Favorable Results From The MASCOT Trial
- MPP cell population: A new potential target for treating infection and allergic inflammation
Translator
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  |  |  |
 |  |  |  |  |  |  |  | ||
| By N2H | |||||||||